Hormone therapy using androgen receptor-signaling inhibitors (ARSi) is a standard treatment for patients with prostate cancer that have either relapsed after surgery and/or radiotherapy or present with metastatic disease at diagnosis [3]. This evidence concerns the gene AR and prostate cancer.